Search

Your search keyword '"Nante, G."' showing total 9 results
Start Over Author "Nante, G." Search Limiters Peer Reviewed
9 results on '"Nante, G."'

3. Safety of vitamin K antagonist treatment for splanchnic vein thrombosis: a multicenter cohort study

Author

Riva, N., Ageno, W., Poli, D., Testa, S., Rupoli, S., Santoro, R., Lerede, T., Piana, A., Carpenedo, M., Nicolini, A., Ferrini, P.M., Tosetto, A., Paoletti, O., Rancan, E., Federici, I., Canafoglia, L., Maggioni, A., Falanga, A., Martini, G., Mangione, C., Contino, L., Bonfanti, C., Gresele, P., Pedrini, S., Morandini, R., Marigo, L., Nante, G., Sivera, P., Pasca, S., Malcangi, G., Ettorre, C.P., Cavallero, G.B., Falco, P., Ruocco, L., Paparo, C., Bucherini, E., Suriano, L., Crisantemo, R., Ria, L., Toma, A., Insana, A., Zanatta, N., Zammataro, N., Iannone, A.M., Oriana, V., Pezzo, M.P., Isu, G., and Molinatti, M.

Published
2015
Full Text
View/download PDF

5. Cognitive decline in the elderly: A double- blind, placebo- controlled multicenter study on efficacy of phosphatidylserine administration

Author

Cenacchi, Teresa, Bertoldin, T., Farina, C., Fiori, M. G., Crepaldi, G., Azzini, C. F., Girardello, R., Bagozzi, B., Garuti, R., Vivaldi, P., Belloni, G., Bordin, A., Durando, M., Lo Storto, M., Bertoni, L., Battistoni, A., Cacace, C., Arduini, P., Bonini, A., Caramia, M. P., Vaglieri, G., Brusomini, A., Donà, G., March, A., Campi, N., Cannas, P., Casson, F., Cavallarin, G., Delia, M., Cristianini, G., Louvier, O., Mello, F., Fameli, R., Urbani de Gheltoff, N., De Candia, O., Nante, G., Cattoni, C., Forte, P. L., Loreggian, M., Targa, A., Mansoldo, G., Noro, G., Meggio, A., Pedrazzi, F., Bonmartini, F., Ruggiano, C., Peruzza, M., Olivari, G., Recaldin, E., Bellunato, C., Rigo, G., Marin, M., Marinangeli, L., Saracino, A., Miceli, O., Lovo, G., Scarpa, R., Battistello, L., Tomat, E., Bernava, B., Olivo, P., Verga, G., Merli, G., Zerman, A. M., Crivellaro, R., Vozza, A., Ziliotto, G. R., Favaretto, V., and Allegro, L.

Published
1993
Full Text
View/download PDF

6. Incidence of Chronic Thromboembolic Pulmonary Hypertension after Pulmonary Embolism

Author

Pengo, Vittorio, Lensing, A. W. A., Prins, M. H., Marchiori, A., Davidson, B. L., Tiozzo, F., Albanese, P., Biasiolo, A., Pegoraro, C., Iliceto, Sabino, Prandoni, Paolo, Razzolini, Renato, Ramondo, A., Bellotto, F., Noventa, Franco, Villanova, C., Barbero, F., Casara, F., Nante, G., Tormene, Daniela, Gerosa, Gino, Testolin, L., Bottio, Tomaso, Piovella, F., Vigano', M., and D'Armini, A.

Subjects
Adult, Male, medicine.medical_specialty, Adolescent, Hypertension, Pulmonary, medicine.medical_treatment, Recurrence, Risk Factors, Thromboembolism, Internal medicine, medicine, Pulmonary angiography, Humans, Cumulative incidence, Pulmonary wedge pressure, Aged, Pulmonary thromboendarterectomy, business.industry, Incidence, Respiratory disease, Age Factors, General Medicine, Odds ratio, Middle Aged, medicine.disease, Pulmonary hypertension, Surgery, Pulmonary embolism, Logistic Models, Chronic Disease, Cardiology, Female, Pulmonary Embolism, business, Follow-Up Studies
Abstract

background Chronic thromboembolic pulmonary hypertension (CTPH) is associated with considerable morbidity and mortality. Its incidence after pulmonary embolism and associated risk factors are not well documented. methods We conducted a prospective, long-term, follow-up study to assess the incidence of symptomatic CTPH in consecutive patients with an acute episode of pulmonary embolism but without prior venous thromboembolism. Patients with unexplained persistent dyspnea during follow-up underwent transthoracic echocardiography and, if supportive findings were present, ventilation–perfusion lung scanning and pulmonary angiography. CTPH was considered to be present if systolic and mean pulmonary-artery pressures exceeded 40 mm Hg and 25 mm Hg, respectively; pulmonary-capillary wedge pressure was normal; and there was angiographic evidence of disease. results The cumulative incidence of symptomatic CTPH was 1.0 percent (95 percent confidence interval, 0.0 to 2.4) at six months, 3.1 percent (95 percent confidence interval, 0.7 to 5.5) at one year, and 3.8 percent (95 percent confidence interval, 1.1 to 6.5) at two years. No cases occurred after two years among the patients with more than two years of follow-up data. The following increased the risk of CTPH: a previous pulmonary embolism (odds ratio, 19.0), younger age (odds ratio, 1.79 per decade), a larger perfusion defect (odds ratio, 2.22 per decile decrement in perfusion), and idiopathic pulmonary embolism at presentation (odds ratio, 5.70). conclusions CTPH is a relatively common, serious complication of pulmonary embolism. Diagnostic and therapeutic strategies for the early identification and prevention of CTPH are needed.

Published
2004
Full Text
View/download PDF

9. Effectiveness of fixed minidose warfarin in the prevention of thromboembolism and vascular death in nonrheumatic atrial fibrillation.

Author

Pengo, Vittorio, Zasso, Antonella, Barbero, Fabio, Banzato, Alberto, Nante, Giovanni, Parissenti, Lucia, John, Nancy, Noventa, Franco, Volta, Sergio Dalla, Pengo, V, Zasso, A, Barbero, F, Banzato, A, Nante, G, Parissenti, L, John, N, Noventa, F, and Dalla Volta, S

Subjects
*WARFARIN, *ATRIAL fibrillation, THROMBOEMBOLISM treatment
Abstract

Adjusted-dose warfarin is effective for stroke prevention in patients with nonrheumatic atrial fibrillation (AF), but the risk of bleeding is high, especially among the elderly. Fixed minidose warfarin is effective in preventing venous thromboembolism with low risk of bleeding and no need for frequent clinical monitoring. Patients > 60 years with nonrheumatic AF were randomized in an open-labeled trial to receive fixed minidose warfarin (1.25 mg/day) or standard adjusted-dose warfarin (International Normalized Ratio [INR] between 2.0 and 3.0). Primary outcome events were ischemic stroke, peripheral or visceral embolism, cerebral or fatal bleeding, and vascular death. Secondary end points were major bleeding, myocardial infarction, and death. This study was discontinued before completion in light of publication of the Stroke Prevention in Atrial Fibrillation III trial, which indicated that low-intensity fixed-dose warfarin treatment (i.e., INR < 1.5) was insufficient for stroke prevention in high-risk patients with nonrheumatic AF. From a total of 1,209 considered patients, 303 were randomized to be studied (150 in the minidose group and 153 in the adjusted-dose group). Mean follow-up was 14.5 months. The rate of cumulative primary events was 11.1% (95% confidence intervals [CI] 4.0 to 18.2) in the fixed minidose group and 6.1% (95% CI 1.1 to 11.1) in the adjusted-dose group (p = 0.29). The rate of ischemic stroke was significantly higher in the minidose group (3.7% vs 0% per year, p = 0.025). Major bleedings were more frequent in standard treatment group (2.6% vs 1% per year, p = 0.19). Most thromboembolic complications occurred at INRs < 1.2, whereas the majority of hemorrhages occurred at INRs > 3.0. No significant difference in primary outcome events was observed in the abbreviated study. However, the significantly increased occurrence of ischemic stroke in the fixed minidose warfarin group suggests that this regimen does not protect patients with nonrheumatic AF. [ABSTRACT FROM AUTHOR]

Published
1998
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results